Molecular ontogeny underlies the benefit of adding venetoclax to hypomethylating agents in newly diagnosed AML patients. Shimony S, Garcia JS, Keating J, Chen EC, et al. Leukemia 2024;38:1494-1500.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Shimony S, Garcia JS, Keating J, Chen EC, et al. Molecular ontogeny underlies the benefit of adding venetoclax to hypomethylating agents in newly diagnosed AML patients. Leukemia 2024;38:1494-1500.
PMID: 38538860